Stephen F. Mahoney - 30 Nov 2022 Form 4 Insider Report for Magenta Therapeutics, Inc. (DNTH)

Reporting relationship: Title: Chief Financial and Operating Officer
Issuer ticker: DNTH
Reported as of: 30 Nov 2022
Net transaction value: +$2,820
SEC form: 4
Accepted by SEC: 02 Dec 2022, 15:23:47 UTC
Prior SEC filing: 01 Aug 2022
Next SEC filing: 01 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Cindy Driscoll, Attorney-in-Fact for Stephen F. Mahoney

Key filing fact

Stephen F. Mahoney filed Form 4 for Magenta Therapeutics, Inc. (DNTH) on 02 Dec 2022.

Key facts

This page summarizes Stephen F. Mahoney's Form 4 filing for Magenta Therapeutics, Inc. (DNTH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Dec 2022, 15:23.

Change

Previous filing in this sequence was filed on 01 Aug 2022.
Current net transaction value: +$2,820.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MGTA transaction

Common Stock

Award

Transaction value: $2,820
Shares: +3,000
Change %: +21%
Price: $0.9400
Shares after: 17,264
Date: 30 Nov 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of June 1, 2022 through November 30, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

Footnote F2

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 1, 2022.

SEC remarks

Title: Chief Financial and Operating Officer